share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Elston George

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Elston George

EyePoint Pharmaceuticals | 4：持股變動聲明-高管 Elston George
美股SEC公告 ·  05/29 10:38
牛牛AI助理已提取核心訊息
George Elston, the Chief Financial Officer of EyePoint Pharmaceuticals, completed a transaction involving the company's common stock on May 25, 2024. Elston exercised options to acquire 7,500 shares at no cost and subsequently sold 3,627 shares at a price of $11.16 per share. The sale resulted in a total market value of $40,477.32. Following these transactions, Elston's direct holdings in EyePoint Pharmaceuticals common stock amounted to 47,480 shares.
George Elston, the Chief Financial Officer of EyePoint Pharmaceuticals, completed a transaction involving the company's common stock on May 25, 2024. Elston exercised options to acquire 7,500 shares at no cost and subsequently sold 3,627 shares at a price of $11.16 per share. The sale resulted in a total market value of $40,477.32. Following these transactions, Elston's direct holdings in EyePoint Pharmaceuticals common stock amounted to 47,480 shares.
EyePoint Pharmicals首席財務官喬治·埃爾斯頓於2024年5月25日完成了一項涉及該公司普通股的交易。埃爾斯頓行使期權免費收購了7,500股股票，隨後以每股11.16美元的價格出售了3,627股股票。此次出售的總市值爲40,477.32美元。這些交易之後，埃爾斯頓直接持有的EyePoint Pharmicals普通股爲47,480股。
EyePoint Pharmicals首席財務官喬治·埃爾斯頓於2024年5月25日完成了一項涉及該公司普通股的交易。埃爾斯頓行使期權免費收購了7,500股股票，隨後以每股11.16美元的價格出售了3,627股股票。此次出售的總市值爲40,477.32美元。這些交易之後，埃爾斯頓直接持有的EyePoint Pharmicals普通股爲47,480股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。